{
    "clinical_study": {
        "@rank": "29926", 
        "arm_group": {
            "arm_group_label": "Pimasertib", 
            "arm_group_type": "Experimental", 
            "description": "Pimasertib taken as assigned in doses between the 45 mg twice a day (BID) up to the recommended phase 2 dose (RP2D) expected to be between 60-75mg BID."
        }, 
        "brief_summary": {
            "textblock": "This is a two-part trial. \"Solid tumor\" in this protocol means solid tumor excluding\n      hepatocellular carcinoma (HCC).\n\n      Part 1: Dose Escalation Phase in subjects with solid tumor (Cohort A) and HCC (Cohort B).\n      The dose will be increased from 45 mg twice a day (BID) with 3+3 cohort method up to the\n      recommended phase 2 dose (RP2D) of pimasertib established as single agent in the global\n      studies for each arm independently.\n\n      Part 2: The Maximum Tolerated Dose (MTD) defined in Part 1 will be confirmed in more\n      subjects in Cohort A (N=18) and Cohort B (N=6) separately."
        }, 
        "brief_title": "A Multicentre, Open Label, Phase I Trial in Japan of the MEK Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Advanced Solid Tumors", 
            "Hepatocellular Carcinoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Neoplasms", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Cohort A: A histologically or cytologically confirmed diagnosis of advanced solid tumors\n        which is either refractory after standard therapy for the disease or for which no\n        effective standard therapy is available. Archived tumor tissue available or biopsy of\n        tumor tissue needs to be performed.\n\n        Cohort B: A histologically or cytologically confirmed diagnosis of advanced hepatocellular\n        carcinoma (HCC) which is either refractory after standard therapy for the disease or for\n        which no effective standard therapy is available. Archived tumor tissue available or\n        biopsy of tumor tissue needs to be performed. Subjects with Child Pugh A.\n\n          -  Male or female Japanese, age \u2265 18 years.\n\n          -  Subject has read and understands the informed consent form and is willing and able to\n             give informed consent. The subject fully understands requirements of the trial and is\n             willing to comply with all trial visits and assessments.\n\n          -  Women of childbearing potential must have a negative blood pregnancy test at the\n             screening visit.\n\n          -  Female subjects of childbearing potential and male subjects with female partners of\n             childbearing potential must be willing to avoid pregnancy by using an adequate method\n             of contraception for 2 weeks prior to, during and four weeks after the last dose\n             investigational medicinal product (IMP).\n\n          -  Life expectancy of at least 3 months\n\n        Exclusion Criteria:\n\n        Hematological abnormality Cohort A: Hematological test abnormalities of Hemoglobin < 9.0\n        g/dL, Neutrophil count < 1.0*10^9/L and Platelet count < 100*10^9/L.\n\n        Cohort B: Hematological test abnormalities of Hemoglobin < 9.0 g/dL, Neutrophil count <\n        1.0*10^9/L, Platelet count < 75*10^9/L, subjects with hepatic encephalopathy\n\n          -  Renal impairment as evidenced by serum creatinine > 1.5*upper limit of normal (ULN),\n             and calculated creatinine clearance < 60 mL/min by Cockcroft-Gault formula.\n\n          -  Liver function abnormality of Total Bilirubin > 1.5*ULN, or aspartate transaminase\n             9AST) or alkaline phosphatase (ALT)> 2.5*ULN. For subjects with HCC or liver\n             involvement AST/ALT > 5*ULN.\n\n          -  History of central nervous system (CNS) metastases, unless subject has been\n             previously treated for CNS metastases\n\n          -  History of difficulty swallowing, malabsorption or other chronic gastro-intestinal\n             disease or conditions\n\n          -  Eastern Cooperative Oncology Group Performance status (ECOG PS) greater than 1.\n\n          -  Has received chemotherapy, immunotherapy, hormonal therapy, biologic therapy, or any\n             other anticancer therapy (including any investigational agent) or surgical\n             intervention within 28 days or 5 half lives for non-cytotoxics of registration.\n\n          -  Baseline corrected QT interval on screening ECG (QTc) \u2265 480 ms or left ventricular\n             ejection fraction (LVEF) < 40% on screening echocardiogram\n\n          -  Cohort B: Subjects with hepatic encephalopathy, remarkable ascites and subjects with\n             history of esophageal varices rupture within 6 months (subjects with symptom\n             improvement after treatment are eligible)\n\n          -  Other serious illness or medical conditions.\n\n          -  Retinal degenerative disease.\n\n          -  Previous treatment with MEK inhibitors.\n\n          -  Legal incapacity or limited legal capacity."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 15, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01668017", 
            "org_study_id": "EMR 200066-010"
        }, 
        "intervention": {
            "arm_group_label": "Pimasertib", 
            "description": "Pimasertib will be supplied as 15 and 30 mg hard gelatin capsules. Pimasertib will be taken orally twice a day continuously. Treatment will be administered in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject, whichever comes first.", 
            "intervention_name": "Pimasertib", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Advanced solid tumors", 
            "Hepatocellular carcinoma", 
            "cancer, liver"
        ], 
        "lastchanged_date": "September 4, 2012", 
        "location": {
            "contact": {
                "phone": "81-3-6853-8630"
            }, 
            "facility": {
                "address": {
                    "city": "Merck Serono Co., Ltd for recruiting locations in", 
                    "country": "Japan"
                }, 
                "name": "Please contact"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicentre, Open Label, Phase I Trial in Japan of the MEK Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy", 
        "overall_contact": {
            "email": "yukito.kuwahara@merckgroup.com", 
            "last_name": "Yukito Kuwahara, Clinical Trial Leader"
        }, 
        "overall_official": {
            "affiliation": "National Cancer Centre Hospital East", 
            "last_name": "Department of GI Oncology/Gastroenterology", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Participants Who Experienced at least one Dose Limiting Toxicity (DLT) During Treatment Cycle 1 (days 1-21) by arm and treatment level", 
            "safety_issue": "Yes", 
            "time_frame": "Days 1-21"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01668017"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of participants who experienced treatment-emergent adverse events (TEAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1 up to approximately Day 84 (end of cycle 4)"
            }, 
            {
                "description": "Maximum concentration (Cmax), time to maximum concentration (tmax), area under the curve from hours 0-24 (AUC0-24), area under the curve over time (AUCt), apparent terminal half-life (t1/2), apparent clearance (CL/f),  apparent clearance at steady-state (CLss/f), apparent volume of distribution at terminal phase (Vz/f), apparent volume of distribution at steady-state (Vss/f), accumulation ratio for AUC (Racc(AUC)), accumulation ratio for Cmax (Racc(Cmax))", 
                "measure": "Pharmacokinetic parameters", 
                "safety_issue": "No", 
                "time_frame": "Day 1 up to approximately Day 84 (end of cycle 4)"
            }, 
            {
                "measure": "Participants best overall response as Assessed by the Investigator", 
                "safety_issue": "No", 
                "time_frame": "Day 1 up to approximately Day 84 (end of cycle 4)"
            }
        ], 
        "source": "Merck KGaA", 
        "sponsors": {
            "collaborator": {
                "agency": "Merck Serono Co., Ltd., Japan", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Merck KGaA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}